PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: Role of HIF1α suppression

Journal of Neuro-Oncology

Volumn 116, Issue 1, 2014, Pages 89-97

  Muh, Carrie R ^a   Joshi, Shweta ^b   Singh, Alok R ^b   Kesari, Santosh ^c   Durden, Donald L ^b   Makale, Milan T ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

2ME2; Angiogenesis; Glioblastoma multiforme; HIF1 ; PI3K; PTEN

Indexed keywords

2 METHOXYESTRADIOL; 2 MORPHOLINO 8 PHENYLCHROMONE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; MORPHOLINES; PTEN PHOSPHOHYDROLASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891832967     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1283-3     Document Type: Article

References (47)

1. Buckner JC (2003) Factors influencing survival in high-grade gliomas. Semin Oncol 30(6 Suppl 19):10-14
2. DeAngelis LM (2001) Brain tumors. N Engl J Med 344(2):114-123
3. Srividya MR et al (2011) Homozygous 10q23/PTEN deletion and its impact on outcome in glioblastoma: a prospective translational study on a uniformly treated cohort of adult patients. Neuropathology 31(4):376-383
4. Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996
5. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061-1068
6. Gallia GL et al (2006) PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 4(10):709-714
7. Scheid MP, Woodgett JR (2003) Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 546(1):108-112
8. Castellino RC, Muh CR, Durden DL (2009) PI-3 kinase-PTEN signaling node: an intercept point for the control of angiogenesis. Curr Pharm Des 15(4):380-388
9. Sun H et al (1999) PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA 96(11):6199-6204
10. Wen S et al (2001) PTEN controls tumor-induced angiogenesis. PNAS 98(8):4622-4627
11. Forsythe JA et al (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16(9):4604-4613
12. 2 sensing. Science 292(5516):464-468
13. Jaakkola P et al (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292(5516):468-472
14. Semenza G (2002) Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 64(5-6):993-998
15. Jiang BH et al (2001) Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12(7):363-369
16. Zhong H et al (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60(6):1541-1545
17. Zundel W et al (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14(4):391-396
18. Alvarez-Tejado M et al (2002) Lack of evidence for the involvement of the phosphoinositide 3-kinase/Akt pathway in the activation of hypoxia-inducible factors by low oxygen tension. J Biol Chem 277(16):13508-13517
19. Arsham AM et al (2002) Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription. J Biol Chem 277(17):15162-15170
20. Mabjeesh NJ et al (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3(4):363-375
21. Kirches E, Warich-Kirches M (2009) 2-methoxyestradiol as a potential cytostatic drug in gliomas? Anticancer Agents Med Chem 9(1):55-65
22. Kang SH et al (2006) Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res 66(24):11991-11997
23. Lis A et al (2004) 2-Methoxyestradiol inhibits proliferation of normal and neoplastic glial cells, and induces cell death, in vitro. Cancer Lett 213:57-65
24. James J et al (2007) Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 25(1):41-48
25. Bruce JY et al (2012) A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Invest New Drugs 30(2):794-802
26. Sweeney C et al (2005) A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 11(18):6625-6633
27. ClinicalTrials.gov. Phase 2 study of panzem nanocrystal colloidal dispersion (NCD) in combination with fixed-dose temozolomide to patients with recurrent glioblastoma multiforme (GBM). http://clinicaltrials.gov/ct2/show/ NCT00481455
28. ClinicalTrials.gov. A phase 2 study with panzem in patients with relapsed or plateau phase multiple myeloma. http://clinicaltrials.gov/ct2/show/ NCT00592579
29. ClinicalTrials.gov. A combination study to determine the safety and efficacy of panzem NCD with avastin in metastatic carcinoid tumors. http://clinicaltrials.gov/ct2/show/NCT00328497
30. Dahut WL et al (2006) Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 5(1):22-27
31. Mooberry SL (2003) New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol 15(6):425-430
32. Duman BB et al (2013) PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer. J BUON 18(1):44-50
33. Sami A, Karsy M (2013) Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding. Tumour Biol 34(4):1991-2002
34. Wischhusen J et al (2003) CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 22(51):8233-8245
35. Garlich JR et al (2008) A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 68(1):206-215
36. Rong Y et al (2005) PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 65(4):1406-1413
37. Andrews NC, Faller DV (1991) A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19(9):2499
38. Peirce SK et al (2011) The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. Cancer Chemother Pharmacol 68(2):325-335
39. Mabjeesh NJ et al (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3:363-375
40. Ricker JL et al (2004) 2-Methoxyestradiol inhibits hypoxia-inducible factor 1α, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res 10:8665-8673
41. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
42. Su JD et al (2003) PTEN and phosphatidylinositol 3′-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res 63(13):3585-3592
43. Said R et al (2013) P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget 4(5):705-714
44. Sermeus A, Michiels C (2011) Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis 2:e164
45. Chen D et al (2003) Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem 278(16):13595-13598
46. Stambolic V et al (2001) Regulation of PTEN transcription by p53. Mol Cell 8(2):317-325
47. Mellinghoff IK et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353(19):2012-2024